Recent news regarding
BeiGene, Ltd. signals a number of key developments. The company announced updates in its
clinical development program for
Ociperlimab (BGB-A1217), followed by a decision to rebrand its
NASDAQ ticker symbol to “ONC”. BeiGene also announced an overhaul to their commercial leadership team and
plans to relocate to Switzerland. The company reported substantial growth in institutional ownership clocking at 45%. Renowned analyst firms such as
JPMorgan Chase & Co. and Guggenheim have forecasted strong price appreciation for BeiGene. It received
Positive CHMP opinions on TEVIMBRA® and U.S. FDA acceptance of a Supplemental New Drug application for BRUKINSA. Biotech's BeiGene Ltd also entered
partnerships with BostonGene, CLL Society and several others to promote research in cancer treatment. Despite a
setback with a discontinued Lung Cancer drug trial, BeiGene remains strong in other areas with
new clinical trials set for 2024 and a rebranding effort to BeOne Medicines.
BeiGene, Ltd. News Analytics from Tue, 23 Jul 2024 07:00:00 GMT to Sun, 27 Apr 2025 02:12:11 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor -2
